Lupin gets FDA OK for generic Myfortic, launches generic Hectorol

Press enter to search
Close search
Open Menu

Lupin gets FDA OK for generic Myfortic, launches generic Hectorol

By Sandra Levy - 12/27/2019

Lupin, in alliance with Concord Biotech has received approval from the Food and Drug Administration for mycophenolic acid delayed-release tablets, in dosage strengths of 180 mg and 360 mg.

The product is the generic of Novartis’ Myfortic delayed-release tablets, 180 mg and 360 mg.

It is indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant; use in combination with cyclosporine and corticosteroids.

The product had a market value of approximately $174 million, according to IQVIA September 2019 data.

Lupin also is debuting doxercalciferol injection, in 4 mcg/2 mL (2 mcg/mL) multi-dose vials, having received approval from the FDA earlier.

Lupin’s product is the generic of Sanofi Genzyme’s Hectorol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials. It is indicated for the treatment of secondary hyperparathyroidism in adult patients with CKD on dialysis.

The product had a market value of approximately $132 million, according to IQVIA October 2019 data.

RELATED TOPICS